The largest biotech IPO on NASDAQ this year: Allogene raised a record $324 million on its pricing, a figure that will likely grow as the underwriters pick up their options.
Allogene is working on a next-generation version of the cell-therapy treatment known as CAR-T, focused on winning the race to the first off-the-shelf CAR-T.
Allogene and Servier plan to start Phase II trials of UCART19 in 2019.
Referring links:
